Equities Analysts Offer Predictions for Biota Pharmaceuticals Inc.’s Q3 2017 Earnings (AVIR)
Biota Pharmaceuticals Inc. (NASDAQ:AVIR) – Stock analysts at Zacks Investment Research issued their Q3 2017 earnings per share estimates for shares of Biota Pharmaceuticals in a research note issued to investors on Thursday. Zacks Investment Research analyst A. Dushyanth forecasts that the firm will post earnings of ($0.14) per share for the quarter.
Biota Pharmaceuticals (NASDAQ:AVIR) last issued its quarterly earnings data on Wednesday, September 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.25 by $0.43. Biota Pharmaceuticals had a negative return on equity of 46.02% and a negative net margin of 272.04%.
Several other analysts have also recently issued reports on AVIR. HC Wainwright initiated coverage on shares of Biota Pharmaceuticals in a report on Wednesday, July 13th. They issued a “buy” rating and a $5.00 price target on the stock. FBR & Co reaffirmed an “outperform” rating on shares of Biota Pharmaceuticals in a report on Tuesday, May 31st.
Shares of Biota Pharmaceuticals (NASDAQ:AVIR) traded up 2.65% on Monday, reaching $1.55. 3,399 shares of the company’s stock traded hands. The stock’s market capitalization is $59.89 million. The company has a 50 day moving average of $1.37 and a 200-day moving average of $1.46. Biota Pharmaceuticals has a 52 week low of $1.23 and a 52 week high of $2.31.
A number of hedge funds have recently added to or reduced their stakes in the stock. Towerview LLC acquired a new stake in Biota Pharmaceuticals during the second quarter valued at $224,000. California Public Employees Retirement System acquired a new stake in Biota Pharmaceuticals during the second quarter valued at $139,000. Gabelli Securities Inc. acquired a new stake in Biota Pharmaceuticals during the second quarter valued at $314,000. Dimensional Fund Advisors LP acquired a new stake in Biota Pharmaceuticals during the second quarter valued at $290,000. Finally, Vanguard Group Inc. acquired a new stake in Biota Pharmaceuticals during the second quarter valued at $1,462,000. Hedge funds and other institutional investors own 34.53% of the company’s stock.
About Biota Pharmaceuticals
Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals Inc, is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options.
Receive News & Ratings for Biota Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biota Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.